Characterized by high incidence and long treatment durations, the breast cancer therapy market represents substantial commercial opportunity for drug developers. CDK4/6 inhibitors (Pfizer’s Ibrance, Novartis’s Kisqali, and Eli Lilly’s Verzenio/Verzenios) are creating new dynamics in the treatment of metastatic HR-positive/HER2-negative disease. Meanwhile, novel HER2-targeted agents, label expansions, and biosimilar entries—all of which will lead to changes in treatment guidelines—will have an impact on sales of current drugs for HER2-positive breast cancer. Furthermore, the approval of PARP inhibitors (AstraZeneca / Merck & Co.’s Lynparza and Pfizer’s Talzenna), immune checkpoint inhibitors (Roche / Genentech / Chugai’s Tecentriq and Merck & Co.’s Keytruda), PI3K inhibitors (Novartis’s Piqray), HER2-targeted agents (Daiichi Sankyo / AstraZeneca’s Enhertu, Seagen / Pfizer’s Tukysa, and MacroGenics’ Margenza), and TROP2-targeted agents (Gilead’s Trodelvy), as well as the anticipated entry of other agents from these drug classes, will diversify treatment options, especially for triple-negative breast cancer.
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Disease Landscape & Forecast will feature continuous updates in 2021 to provide timely insights and analyses as meaningful indication-specific news and events unfold.